Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 5% - Should You Sell?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) was down 5% during trading on Friday . The company traded as low as $13.12 and last traded at $12.98. Approximately 88,397 shares changed hands during trading, a decline of 96% from the average daily volume of 2,276,885 shares. The stock had previously closed at $13.67.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on ARQT shares. Mizuho raised their price target on Arcutis Biotherapeutics from $20.00 to $21.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 26th. Jefferies Financial Group raised their price target on Arcutis Biotherapeutics from $16.00 to $19.00 and gave the stock a "buy" rating in a research report on Tuesday, March 11th. HC Wainwright reiterated a "buy" rating and set a $19.00 price objective on shares of Arcutis Biotherapeutics in a report on Thursday, April 3rd. Guggenheim reiterated a "buy" rating on shares of Arcutis Biotherapeutics in a report on Thursday, April 3rd. Finally, The Goldman Sachs Group increased their price objective on Arcutis Biotherapeutics from $13.00 to $15.00 and gave the stock a "neutral" rating in a report on Thursday, February 27th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Arcutis Biotherapeutics presently has an average rating of "Moderate Buy" and an average price target of $18.80.

Arcutis Biotherapeutics Stock Performance

The company has a quick ratio of 2.38, a current ratio of 2.46 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $1.56 billion, a P/E ratio of -7.31 and a beta of 1.87. The stock has a fifty day moving average of $14.24 and a 200-day moving average of $13.74.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.01. The business had revenue of $65.85 million during the quarter, compared to the consensus estimate of $64.80 million. Arcutis Biotherapeutics had a negative return on equity of 119.11% and a negative net margin of 140.97%. On average, research analysts anticipate that Arcutis Biotherapeutics, Inc. will post -1.33 EPS for the current year.

Insider Buying and Selling at Arcutis Biotherapeutics

In other news, insider Patrick Burnett sold 2,819 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $13.03, for a total transaction of $36,731.57. Following the completion of the transaction, the insider now directly owns 167,043 shares in the company, valued at approximately $2,176,570.29. The trade was a 1.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Patrick J. Heron bought 2,520 shares of Arcutis Biotherapeutics stock in a transaction dated Wednesday, May 21st. The shares were acquired at an average price of $13.66 per share, with a total value of $34,423.20. Following the completion of the purchase, the director now directly owns 20,014 shares in the company, valued at $273,391.24. This trade represents a 14.40% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 45,913 shares of company stock worth $656,966 over the last ninety days. 9.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new position in shares of Arcutis Biotherapeutics during the 4th quarter worth approximately $34,000. Venturi Wealth Management LLC bought a new position in shares of Arcutis Biotherapeutics during the 4th quarter worth approximately $46,000. Amalgamated Bank boosted its stake in shares of Arcutis Biotherapeutics by 39.4% during the 1st quarter. Amalgamated Bank now owns 3,723 shares of the company's stock worth $58,000 after acquiring an additional 1,053 shares during the period. KBC Group NV bought a new position in shares of Arcutis Biotherapeutics during the 1st quarter worth approximately $84,000. Finally, Nkcfo LLC bought a new position in shares of Arcutis Biotherapeutics during the 1st quarter worth approximately $109,000.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.